Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25571221 | 0.86 | PPARG (0.41) | AKT1CTSLCTSBCTSSNPC1 | |
| SCHEMBL25571225 | 0.84 | RECQL (0.40) | AKT1CTSLCTSBCTSSMEN1 | |
| SCHEMBL1644251 | 0.84 | HSP90AA1 (0.60) | AKT1POLBCTSLCTSBCTSS | |
| SCHEMBL25571223 | 0.84 | ABCB1 (0.48) | SMN1; SMN2MEN1KMT2ATDP1CYP3A4 | |
| SCHEMBL25571222 | 0.83 | HTT (0.50) | KMT2ACA1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL25244239 | 0.83 | CES2 (0.42) | CTSSMEN1NPC1RAB9AKMT2A | |
| SCHEMBL25571227 | 0.83 | KMT2A (0.49) | AKT1POLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8173651 | 0.83 | POLB (0.67) | AKT1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4514673 | 0.83 | AKT1 (0.48) | AKT1POLBCTSLCTSBCTSS | |
| SCHEMBL25571224 | 0.82 | ABCB1 (0.49) | SMN1; SMN2MEN1NPC1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907131-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8907131-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140342999-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140342999-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8729111-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729111-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20140031429-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | KOYA KEIZO (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031429-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | KOYA KEIZO (US) | 2014-01-30 | — | — | US | disclosed |
| US-8455686-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455686-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120095103-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095103-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120065235-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065235-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-03-15 | — | — | US | disclosed |
| US-8093425-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093425-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090023736-A1 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023736-A1 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023736-A1 | Compounds for treating proliferative disorders | HSP90AB1, HSF1, HSP90B1 | AKT1 3231/4885POLB 1588/4885CTSL 2242/4885 |
| US-20120065235-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | AKT1 3231/4885POLB 1588/4885CTSL 2242/4885 |
| US-20120095103-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | AKT1 3231/4885POLB 1588/4885CTSL 2242/4885 |
| US-20140342999-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | AKT1 3231/4885POLB 1588/4885CTSL 2242/4885 |
| US-20140031429-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | AKT1 3231/4885POLB 1588/4885CTSL 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.